Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
Search for:
Elafibranor63 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A01204 | 34829876 | Biomedicines | Estimating Drug Efficacy with a Diet-Induced NASH Model in Chimeric Mice with Humanized Livers. | 2021 | Details |
| A02030 | 34526653 | Commun Biol | Modelling human liver fibrosis in the context of non-alcoholic steatohepatitis using a microphysiological system. | 2021 | Details |
| A02443 | 34370218 | Clin J Gastroenterol | Efficacy of elafibranor in patients with liver abnormalities especially non-alcoholic steatohepatitis: a systematic review and meta-analysis. | 2021 | Details |
| A03482 | 33987427 | Ann Transl Med | Non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH)-related liver fibrosis: mechanisms, treatment and prevention. | 2021 | Details |
| A04016 | 33788377 | Liver Int | Elafibranor and liraglutide improve differentially liver health and metabolism in a mouse model of non-alcoholic steatohepatitis. | 2021 | Details |
| A04097 | 33761646 | Medicine (Baltimore) | The efficacy of novel metabolic targeted agents and natural plant drugs for nonalcoholic fatty liver disease treatment: A PRISMA-compliant network meta-analysis of randomized controlled trials. | 2021 | Details |
| A04338 | 33658534 | Sci Rep | Beneficial effects of elafibranor on NASH in E3L.CETP mice and differences between mice and men. | 2021 | Details |
| A04643 | 33553970 | Hepatol Commun | Human Nonalcoholic Steatohepatitis on a Chip. | 2020 | Details |
| A04937 | 33444606 | Metabolism | Elafibranor improves diet-induced nonalcoholic steatohepatitis associated with heart failure with preserved ejection fraction in Golden Syrian hamsters. | 2021 | Details |
| A05080 | 33385317 | J Dig Dis | Efficacy and safety of drugs for nonalcoholic steatohepatitis. | 2021 | Details |
| A05119 | 33368954 | Diabetes Obes Metab | Pioglitazone and bariatric surgery are the most effective treatments for non-alcoholic steatohepatitis: A hierarchical network meta-analysis. | 2021 | Details |
| A05245 | 33326461 | PLoS One | The pharmacodynamic and differential gene expression analysis of PPAR α/δ agonist GFT505 in CDAHFD-induced NASH model. | 2020 | Details |
| A05376 | 33278029 | Pharmacotherapy | Emerging therapies for the treatment of nonalcoholic steatohepatitis: A systematic review. | 2021 | Details |
| A05793 | 33115209 | Diabetes Metab J | Nonalcoholic Fatty Liver Disease: A Drug Revolution Is Coming. | 2020 | Details |
| A07125 | 32613381 | Cell Biol Toxicol | Human hepatic in vitro models reveal distinct anti-NASH potencies of PPAR agonists. | 2020 | Details |
| A07827 | 32343209 | Radiology | Advanced MRI of Liver Fibrosis and Treatment Response in a Rat Model of Nonalcoholic Steatohepatitis. | 2020 | Details |
| A08327 | 32151660 | Metabolism | Current and emerging pharmacological options for the treatment of nonalcoholic steatohepatitis. | 2020 | Details |
| A08581 | 32052857 | Hepatology | New Drugs for NASH and HIV Infection: Great Expectations for a Great Need. | 2020 | Details |
| A08799 | 31981449 | Clin Transl Sci | A 3-week nonalcoholic steatohepatitis mouse model shows elafibranor benefits on hepatic inflammation and cell death. | 2020 | Details |
| A08933 | 31931543 | Z Gastroenterol | [What is the (right) target for non-alcoholic fatty liver disease (NAFLD)?] | 2020 | Details |
| A09012 | 31905025 | Am J Physiol Gastrointest Liver Physiol | Investigating fibrosis and inflammation in an ex vivo NASH murine model. | 2020 | Details |
| A09074 | 31883514 | BMC Gastroenterol | Validity of biopsy-based drug effects in a diet-induced obese mouse model of biopsy-confirmed NASH. | 2019 | Details |
| A09096 | 31877771 | Cells | Anti-NASH Drug Development Hitches a Lift on PPAR Agonism. | 2019 | Details |
| A09774 | 31614690 | Int J Mol Sci | Exploration and Development of PPAR Modulators in Health and Disease: An Update of Clinical Evidence. | 2019 | Details |
| A10014 | 31523999 | Expert Opin Investig Drugs | Elafibranor: a potential drug for the treatment of nonalcoholic steatohepatitis (NASH). | 2019 | Details |
| A10083 | 31495973 | Hepatol Res | Phase 3 drug pipelines in the treatment of non-alcoholic steatohepatitis. | 2019 | Details |
| A11132 | 31028903 | Pharmacol Res | Elafibranor restricts lipogenic and inflammatory responses in a human skin stem cell-derived model of NASH. | 2019 | Details |
| A11226 | 30986904 | Int J Mol Sci | Human Multilineage 3D Spheroids as a Model of Liver Steatosis and Fibrosis. | 2019 | Details |
| A12332 | 30511198 | Dig Dis Sci | Disease Progression and Pharmacological Intervention in a Nutrient-Deficient Rat Model of Nonalcoholic Steatohepatitis. | 2018 | Details |
| A12660 | 30341231 | Postgrad Med J | Pharmacological interventions for non-alcoholic fatty liver disease: a systematic review and network meta-analysis. | 2018 | Details |
| A12835 | 30261763 | Expert Rev Gastroenterol Hepatol | An update on the recent advances in antifibrotic therapy. | 2018 | Details |
| A13228 | 30074500 | Curr Opin Endocrinol Diabetes Obes | Nonalcoholic steatohepatitis, obesity, and cardiac dysfunction. | 2018 | Details |
| A13453 | 29964161 | Pharmacol Res | Human-based systems: Mechanistic NASH modelling just around the corner? | 2018 | Details |
| A13470 | 29956213 | Adv Exp Med Biol | Current Prevention and Treatment Options for NAFLD. | 2018 | Details |
| A13975 | 29662003 | Int J Mol Sci | PPAR Agonists and Metabolic Syndrome: An Established Role? | 2018 | Details |
| A14424 | 29413959 | Redox Biol | Role of gut microbiota and oxidative stress in the progression of non-alcoholic fatty liver disease to hepatocarcinoma: Current and innovative therapeutic approaches. | 2018 | Details |
| A14513 | 29375204 | World J Gastroenterol | Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis. | 2018 | Details |
| A14771 | 29247356 | J Gastroenterol | Current and future pharmacological therapies for NAFLD/NASH. | 2017 | Details |
| A14850 | 29204050 | World J Gastroenterol | Current and emerging pharmacological therapy for non-alcoholic fatty liver disease. | 2017 | Details |
| A15013 | 29128056 | Clin Liver Dis | Emerging Treatments for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. | 2017 | Details |
| A15946 | 28641031 | Expert Opin Drug Saf | Treatment options for nonalcoholic steatohepatitis - a safety evaluation. | 2017 | Details |
| A15959 | 28637104 | Korean J Gastroenterol | [Treatment Options in Non-alcoholic Fatty Liver Disease]. | 2017 | Details |
| A16627 | 28276821 | Expert Rev Gastroenterol Hepatol | Current and future treatment options in non-alcoholic steatohepatitis (NASH). | 2017 | Details |
| A17595 | 27727520 | Liver Int | The therapeutic landscape of non-alcoholic steatohepatitis. | 2016 | Details |
| A17704 | 27646933 | Gut | Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease. | 2016 | Details |
| A17842 | 27543499 | Br Med Bull | Non-alcoholic fatty liver disease in 2016. | 2016 | Details |
| A17895 | 27493105 | Ann Hepatol |  NASH: A glance at the landscape of pharmacological treatment. | 2017 | Details |
| A18671 | 27003143 | Dig Dis Sci | Novel Pharmacotherapy Options for NASH. | 2016 | Details |
| A18909 | 26874076 | Gastroenterology | Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening. | 2016 | Details |
| A30071 | 33024711 | MethodsX | Flow cytometric quantification of neutral lipids in a human skin stem cell-derived model of NASH. | 2020 | Details |
| A31047 | 31321239 | Biomed Res Int | Elafibranor Inhibits Chronic Kidney Disease Progression in NASH Mice. | 2019 | Details |
| A31059 | 31294056 | Data Brief | Transcriptomics data of a human in vitro model of non-alcoholic steatohepatitis exposed to elafibranor. | 2019 | Details |
| A31100 | 31227742 | Sci Rep | Combined obeticholic acid and elafibranor treatment promotes additive liver histological improvements in a diet-induced ob/ob mouse model of biopsy-confirmed NASH. | 2019 | Details |
| A31571 | 30271738 | J Clin Transl Hepatol | Future Pharmacotherapy for Non-alcoholic Steatohepatitis (NASH): Review of Phase 2 and 3 Trials. | 2018 | Details |
| A43317 | 31985310 | Expert Opin Investig Drugs | Prof Jörn Schattenberg sheds light on key treatment and diagnostic approaches to nonalcoholic steatohepatitis (NASH). | 2020 | Details |
| A43318 | 31984804 | Expert Opin Investig Drugs | NASH and NAFLD: emerging drugs, therapeutic targets and translational and clinical challenges. | 2020 | Details |
| A44547 | 28277800 | Expert Rev Clin Pharmacol | Emerging therapies for NASH - the future is now. | 2017 | Details |
| A44575 | 28135159 | JPEN J Parenter Enteral Nutr | JPEN Journal Club 25. Study Design. | 2017 | Details |
| A44813 | 27236162 | Ann Hepatol | Elafibranor for the treatment of NAFLD: One pill, two molecular targets and multiple effects in a complex phenotype. | 2017 | Details |
| A48725 | 30602573 | Clin Sci (Lond) | Elafibranor interrupts adipose dysfunction-mediated gut and liver injury in mice with alcoholic steatohepatitis. | 2019 | Details |
| A50241 | 35461369 | Sci Rep | Effects of ALT-801, a GLP-1 and glucagon receptor dual agonist, in a translational mouse model of non-alcoholic steatohepatitis. | 2022 | Details |
| A50780 | 35269515 | Cells | Transcriptomics Reveals Discordant Lipid Metabolism Effects between In Vitro Models Exposed to Elafibranor and Liver Samples of NAFLD Patients after Bariatric Surgery. | 2022 | Details |
| A51306 | 35735253 | Hepatol Commun | Combinations of an acetyl CoA carboxylase inhibitor with hepatic lipid modulating agents do not augment antifibrotic efficacy in preclinical models of NASH and fibrosis. | 2022 | Details |